Author

I. Clement

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Approach:experimental assay· 1 Research Focus:protein structure prediction· 1 Research Focus:spatial domain detection· 1

Frequent Co-Authors

A.-M. Mes-Masson· 2 shared D. Provencher· 2 shared F. Rodier· 2 shared K. Rahimi· 2 shared M. Skulimowski· 2 shared E. Carmona· 1 shared H. Fleury· 1 shared J. Bourbonnais· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A.-M. Mes-Masson

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A senescence-like state is beneficial for ovarian cancer treatment

M. Skulimowski, L. Calvo Gonzalez, S. Cheng, I. Clement, L. Portelance, Y. Zhan, E. Carmona, J. Lafontaine, M. Deladurantaye, K. Rahimi, D. Provencher, A.-M. Mes-Masson, F. Rodier

This study shows that senescence in ovarian cancer cells after chemotherapy correlates with better patient survival, suggesting senescence could be a therapeutic target.

bioRxiv · Sep 30, 2023 · PreprintCancer Biology

53BP1 mediates sensitivity to chemotherapy and is associated with poor clinical outcomes in high-grade serous ovarian cancer

M. Skulimowski, J. Bourbonnais, N. Malaquin, H. Fleury, I. Clement, L. Communal, K. Rahimi, D. Provencher, A.-M. Mes-Masson, F. Rodier

This study shows that high 53BP1 levels in ovarian cancer are linked to poor survival and chemotherapy resistance, suggesting it could be a therapeutic target.

bioRxiv · Sep 30, 2023 · PreprintCancer Biology